top of page
Brent Warner, MBA
Brent Warner serves as CEO of Protego Biopharma with over 15 years of biopharmaceutical experience across rare diseases, gene therapy and other therapeutic categories.
Prior to joining Protego, Mr. Warner was President of Gene Therapy at Poseida Therapeutics (NASDAQ: PSTX) leading advancements across genetic diseases, and overseeing research / pre-clinical development of non-viral gene therapy programs and platform technologies (piggyBac DNA insertion system, nanoparticles, Cas-CLOVER gene editing). Mr. Warner was previously with Novartis as Vice President, Gene Therapy and Rare Disease, where he was responsible for building a division to commercialize multiple rare disease therapies, having led the successful launches of ZOLGENSMA and LUXTURNA. His prior roles include serving as a U.S. commercial leader in Hemophilia A at BioMarin Pharmaceuticals working on efforts to advance ROCTAVIAN. He held a variety of strategic and operational U.S. and ex-U.S. roles at Biogen with the predominate focus on launching SPINRAZA in multiple countries, and in commercial launch roles across Hematology, Immunology, Oncology, and Medical Devices at Baxalta, now a wholly owned subsidiary of Takeda.

Prior to those roles, Mr. Warner held several strategic roles in consulting organizations and a global lead role within a consumer goods company. Mr. Warner has an MBA with an emphasis in marketing and finance and a Bachelor of Business Administration degree, both from Northwood University in Michigan.

Mr. Warner serves on the board of Cure Rare Disease, a non-profit organization focused on enabling the development of life-saving genetic medicines for rare and ultra-rare patient populations.
bottom of page